Research Article
BibTex RIS Cite
Year 2023, , 212 - 217, 28.03.2023
https://doi.org/10.33808/clinexphealthsci.1099582

Abstract

References

  • Umar RM, Apikoglu-Rabus S, Yumuk PF. Significance of a clinical pharmacist-led comprehensive medication management program for hospitalized oncology patients. Int J Clin Pharm [Internet]. 2020;42(2):652–61. Available from: https://doi.org/10.1007/s11096-020-00992-8
  • Delpeuch A, Leveque D, Gourieux B, Herbrecht R. Impact of clinical pharmacy services in a hematology/oncology inpatient setting. Anticancer Res. 2015;35(1):457–60.
  • Thanacoody R. Drug interactions. Whittlesea C, Hodson K, editors. Clinical Pharmacy and Therapeutics. China: Elsevier; 2019.p53-65.
  • Wiffen P, Mitchell M, Snelling M SN. Oxford Handbook of Clinical Pharmacy. 2012.
  • Wf Van Leeuwen R, Swart EL, Boom FA, Schuitenmaker MS HJ. Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method. 2010;
  • Lopez-Martin C, Garrido Siles M, Alcaide-Garcia J FF V. Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. 2014;
  • Conde-Estévez D. Targeted cancer therapy: interactions with other medicines. Clin Transl Oncol. 2017;19(1):21-30.
  • Ismail M, Khan S, Khan F, Noor S, Sajid H, Yar S, et al. Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy. BMC Cancer. 2020;20(1):1–9.
  • Umar RM. Drug-drug interactions between antiemetics used in cancer patients. J Oncol Sci [Internet]. 2018; Available from: https://linkinghub.elsevier.com/retrieve/pii/S2452336418300141
  • Leveque D, Delpeuch A, Gourieux B. New anticancer agents: Role of clinical pharmacy services. Anticancer Res. 2014;34(4):1573–8.
  • Popa MA, Wallace KJ, Brunello A, Extermann M, Balducci L. Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol [Internet]. 2014;5(3):307–14. Available from: http://dx.doi.org/10.1016/j.jgo.2014.04.002
  • Han JM, Ah YM, Suh SY, Jung SH, Hahn HJ, Im SA, et al. Clinical and economic impact of pharmacists’ intervention in a large volume chemotherapy preparation unit. Int J Clin Pharm. 2016;38(5):1124–32.
  • Chaudhari SJ. Methodology for Gender Identification , Classification and Recognition of Human Age. Int J Comput Appl [Internet]. 2015;(Ncac):5–10. Available from: https://research.ijcaonline.org/ncac2015/number2/ncac175023.pdf LK - https://academic.microsoft.com/paper/2375104003
  • Bayraktar-Ekincioglu A, Demirkan K, Keskin B, Aslantas O, Ozdemir E. Potential drug interactions and side effects in an outpatient oncology clinic: A retrospective descriptive study. Eur J Hosp Pharm. 2014;21(4):216–21.
  • Holweger K, Bokemeyer C, Lipp HP. Accurate measurement of individual glomerular filtration rate in cancer patients: An ongoing challenge. J Cancer Res Clin Oncol. 2005;131(9):559–67.
  • Vayalil RK, Shetty KJ, Mateti UV. Assessment of potential drug-drug interactions in an oncology unit of a tertiary care teaching hospital. Indian J Med Paediatr Oncol. 2018;39(4):436–42.
  • Rashdan S, Yang H, Le T, Selby C, Gerber DE, Alvarez CA. Prevalence and Significance of Potential Pharmacokinetic Drug–Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials. Clin Drug Investig [Internet]. 2021;41(2):161–7. Available from: https://doi.org/10.1007/s40261-020-00994-4
  • Akbulut M, Urun Y. Onco-cardiology: Drug-drug interactions of antineoplastic and cardiovascular drugs. Crit Rev Oncol Hematol [Internet]. 2020;145(March 2019):102822. Available from: https://doi.org/10.1016/j.critrevonc.2019.102822
  • Ramos-Esquivel A, Víquez-Jaikel A, Fernández C. Potential drug-drug and herb-drug interactions in patients with cancer: A prospective study of medication surveillance. J Oncol Pract. 2017;13(7):e613–20.
  • Bibi R, Azhar S, Iqbal A, Jabeen H, Kalsoom UE, Iqbal MM, et al. Prevalence of potential drug-drug interactions in breast cancer patients and determination of their risk factors. J Oncol Pharm Pract. 2021;27(7):1616–22.
  • Alkan A, Yaşar A, Karcı E, Köksoy EB, Ürün M, Şenler FÇ, et al. Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients. Support Care Cancer. 2017;25(1):229–36.
  • Ramasubbu SK, Mahato SK, Agnihotri A, Pasricha RK, Nath UK, Das B. Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: A prospective study in a tertiary care teaching hospital. Cancer Treat Res Commun [Internet]. 2021;26:100277. Available from: https://doi.org/10.1016/j.ctarc.2020.100277
  • Voll ML, Yap KD, Terpstra WE, Crul M. Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs. Pharm World Sci. 2010;32(5):575–80.
  • Paul T, Palatty P, Adnan M, George T, Rao S, Baliga M. Audit of drug-drug interactions and adverse drug reactions due to polypharmacy in older cancer patients: First report from India. Indian J Cancer. 2020;57(4):405–10.
  • Lopez-Martin C, Garrido Siles M, Alcaide-Garcia J, Faus Felipe V. Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. Int J Clin Pharm. 2014;36(6):1251–9.
  • Vecchia S, Orlandi E, Confalonieri C, Damonti E, Riva A, Sartori A, et al. Prevalence study on potential drug–drug interaction in cancer patients in Piacenza hospital’s Onco-Haematology department. J Oncol Pharm Pract. 2018;24(7):490–3.
  • Mousavi M, Hayatshahi A, Sarayani A, Hadjibabaie M, Javadi M, Torkamandi H, et al. Impact of clinical pharmacist-based parenteral nutrition service for bone marrow transplantation patients: a randomized clinical trial. Support Care Cancer. 2013;21(12):3441–8.
  • Han JM, Ah YM, Suh SY, Jung SH, Hahn HJ, Im SA, et al. Clinical and economic impact of pharmacists’ intervention in a large volume chemotherapy preparation unit. Int J Clin Pharm. 2016;38(5):1124–32.

The Prevalence of Drug-Drug Interactions and Reported Therapy Related Side Effects in Oncology Out-Patients

Year 2023, , 212 - 217, 28.03.2023
https://doi.org/10.33808/clinexphealthsci.1099582

Abstract

Objective: The use of multiple medications in cancer patients is unavoidable; thus, adverse drug-drug interactions are frequent. This study aims to assess the prevalence of potential drug interactions in oncology patients visiting the outpatient chemotherapy unit.
Method: Demographic and health-related information of patients visiting an outpatient chemotherapy unit was recorded using a pre-prepared form. A comprehensive list of all concurrently used medications was compiled and checked for interactions with the Micromedex online drug interaction tool.
Results: A total of 179 adult patients were included. We recorded an average of 9.3 drugs per patient with 79 patients using more than 10 drugs. A total of 1671 drugs including 303 chemotherapeutic agents were assessed for drug-drug interactions. A total of 374 interactions, of which 203 were significant, were recorded in 118 (65.9%) patients with an average of 3.2 interactions per patient. Only 46 major interactions were recorded for anticancer agents. Cyclophosphamide (n=13) and cisplatin (n=12) were involved in most interactions. The number of interactions correlated with the number of drugs used (p=.001) and the presence of comorbidities (p=.002). The presence of comorbidities increased the risk of interaction by 1.21 (p=.04). Recorded side effects were not correlated to drug interactions.
Conclusion: Medication review in cancer patients is essential in establishing all medications used by patients. Routine assessment in terms of potential drug interactions and evaluation of these interactions by a qualified pharmacist may help in optimizing patient outcomes.

References

  • Umar RM, Apikoglu-Rabus S, Yumuk PF. Significance of a clinical pharmacist-led comprehensive medication management program for hospitalized oncology patients. Int J Clin Pharm [Internet]. 2020;42(2):652–61. Available from: https://doi.org/10.1007/s11096-020-00992-8
  • Delpeuch A, Leveque D, Gourieux B, Herbrecht R. Impact of clinical pharmacy services in a hematology/oncology inpatient setting. Anticancer Res. 2015;35(1):457–60.
  • Thanacoody R. Drug interactions. Whittlesea C, Hodson K, editors. Clinical Pharmacy and Therapeutics. China: Elsevier; 2019.p53-65.
  • Wiffen P, Mitchell M, Snelling M SN. Oxford Handbook of Clinical Pharmacy. 2012.
  • Wf Van Leeuwen R, Swart EL, Boom FA, Schuitenmaker MS HJ. Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method. 2010;
  • Lopez-Martin C, Garrido Siles M, Alcaide-Garcia J FF V. Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. 2014;
  • Conde-Estévez D. Targeted cancer therapy: interactions with other medicines. Clin Transl Oncol. 2017;19(1):21-30.
  • Ismail M, Khan S, Khan F, Noor S, Sajid H, Yar S, et al. Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy. BMC Cancer. 2020;20(1):1–9.
  • Umar RM. Drug-drug interactions between antiemetics used in cancer patients. J Oncol Sci [Internet]. 2018; Available from: https://linkinghub.elsevier.com/retrieve/pii/S2452336418300141
  • Leveque D, Delpeuch A, Gourieux B. New anticancer agents: Role of clinical pharmacy services. Anticancer Res. 2014;34(4):1573–8.
  • Popa MA, Wallace KJ, Brunello A, Extermann M, Balducci L. Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol [Internet]. 2014;5(3):307–14. Available from: http://dx.doi.org/10.1016/j.jgo.2014.04.002
  • Han JM, Ah YM, Suh SY, Jung SH, Hahn HJ, Im SA, et al. Clinical and economic impact of pharmacists’ intervention in a large volume chemotherapy preparation unit. Int J Clin Pharm. 2016;38(5):1124–32.
  • Chaudhari SJ. Methodology for Gender Identification , Classification and Recognition of Human Age. Int J Comput Appl [Internet]. 2015;(Ncac):5–10. Available from: https://research.ijcaonline.org/ncac2015/number2/ncac175023.pdf LK - https://academic.microsoft.com/paper/2375104003
  • Bayraktar-Ekincioglu A, Demirkan K, Keskin B, Aslantas O, Ozdemir E. Potential drug interactions and side effects in an outpatient oncology clinic: A retrospective descriptive study. Eur J Hosp Pharm. 2014;21(4):216–21.
  • Holweger K, Bokemeyer C, Lipp HP. Accurate measurement of individual glomerular filtration rate in cancer patients: An ongoing challenge. J Cancer Res Clin Oncol. 2005;131(9):559–67.
  • Vayalil RK, Shetty KJ, Mateti UV. Assessment of potential drug-drug interactions in an oncology unit of a tertiary care teaching hospital. Indian J Med Paediatr Oncol. 2018;39(4):436–42.
  • Rashdan S, Yang H, Le T, Selby C, Gerber DE, Alvarez CA. Prevalence and Significance of Potential Pharmacokinetic Drug–Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials. Clin Drug Investig [Internet]. 2021;41(2):161–7. Available from: https://doi.org/10.1007/s40261-020-00994-4
  • Akbulut M, Urun Y. Onco-cardiology: Drug-drug interactions of antineoplastic and cardiovascular drugs. Crit Rev Oncol Hematol [Internet]. 2020;145(March 2019):102822. Available from: https://doi.org/10.1016/j.critrevonc.2019.102822
  • Ramos-Esquivel A, Víquez-Jaikel A, Fernández C. Potential drug-drug and herb-drug interactions in patients with cancer: A prospective study of medication surveillance. J Oncol Pract. 2017;13(7):e613–20.
  • Bibi R, Azhar S, Iqbal A, Jabeen H, Kalsoom UE, Iqbal MM, et al. Prevalence of potential drug-drug interactions in breast cancer patients and determination of their risk factors. J Oncol Pharm Pract. 2021;27(7):1616–22.
  • Alkan A, Yaşar A, Karcı E, Köksoy EB, Ürün M, Şenler FÇ, et al. Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients. Support Care Cancer. 2017;25(1):229–36.
  • Ramasubbu SK, Mahato SK, Agnihotri A, Pasricha RK, Nath UK, Das B. Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: A prospective study in a tertiary care teaching hospital. Cancer Treat Res Commun [Internet]. 2021;26:100277. Available from: https://doi.org/10.1016/j.ctarc.2020.100277
  • Voll ML, Yap KD, Terpstra WE, Crul M. Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs. Pharm World Sci. 2010;32(5):575–80.
  • Paul T, Palatty P, Adnan M, George T, Rao S, Baliga M. Audit of drug-drug interactions and adverse drug reactions due to polypharmacy in older cancer patients: First report from India. Indian J Cancer. 2020;57(4):405–10.
  • Lopez-Martin C, Garrido Siles M, Alcaide-Garcia J, Faus Felipe V. Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. Int J Clin Pharm. 2014;36(6):1251–9.
  • Vecchia S, Orlandi E, Confalonieri C, Damonti E, Riva A, Sartori A, et al. Prevalence study on potential drug–drug interaction in cancer patients in Piacenza hospital’s Onco-Haematology department. J Oncol Pharm Pract. 2018;24(7):490–3.
  • Mousavi M, Hayatshahi A, Sarayani A, Hadjibabaie M, Javadi M, Torkamandi H, et al. Impact of clinical pharmacist-based parenteral nutrition service for bone marrow transplantation patients: a randomized clinical trial. Support Care Cancer. 2013;21(12):3441–8.
  • Han JM, Ah YM, Suh SY, Jung SH, Hahn HJ, Im SA, et al. Clinical and economic impact of pharmacists’ intervention in a large volume chemotherapy preparation unit. Int J Clin Pharm. 2016;38(5):1124–32.
There are 28 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Articles
Authors

Rashida Muhammad Umar 0000-0001-8902-7274

Zeynep Yeşim Can 0000-0002-1444-1355

Ece Güven 0000-0002-9053-5038

Emine Karataş Koçberber This is me 0000-0003-2803-0992

Omer Fatih Olmez 0000-0001-7934-7039

Publication Date March 28, 2023
Submission Date April 7, 2022
Published in Issue Year 2023

Cite

APA Muhammad Umar, R., Can, Z. Y., Güven, E., Karataş Koçberber, E., et al. (2023). The Prevalence of Drug-Drug Interactions and Reported Therapy Related Side Effects in Oncology Out-Patients. Clinical and Experimental Health Sciences, 13(1), 212-217. https://doi.org/10.33808/clinexphealthsci.1099582
AMA Muhammad Umar R, Can ZY, Güven E, Karataş Koçberber E, Olmez OF. The Prevalence of Drug-Drug Interactions and Reported Therapy Related Side Effects in Oncology Out-Patients. Clinical and Experimental Health Sciences. March 2023;13(1):212-217. doi:10.33808/clinexphealthsci.1099582
Chicago Muhammad Umar, Rashida, Zeynep Yeşim Can, Ece Güven, Emine Karataş Koçberber, and Omer Fatih Olmez. “The Prevalence of Drug-Drug Interactions and Reported Therapy Related Side Effects in Oncology Out-Patients”. Clinical and Experimental Health Sciences 13, no. 1 (March 2023): 212-17. https://doi.org/10.33808/clinexphealthsci.1099582.
EndNote Muhammad Umar R, Can ZY, Güven E, Karataş Koçberber E, Olmez OF (March 1, 2023) The Prevalence of Drug-Drug Interactions and Reported Therapy Related Side Effects in Oncology Out-Patients. Clinical and Experimental Health Sciences 13 1 212–217.
IEEE R. Muhammad Umar, Z. Y. Can, E. Güven, E. Karataş Koçberber, and O. F. Olmez, “The Prevalence of Drug-Drug Interactions and Reported Therapy Related Side Effects in Oncology Out-Patients”, Clinical and Experimental Health Sciences, vol. 13, no. 1, pp. 212–217, 2023, doi: 10.33808/clinexphealthsci.1099582.
ISNAD Muhammad Umar, Rashida et al. “The Prevalence of Drug-Drug Interactions and Reported Therapy Related Side Effects in Oncology Out-Patients”. Clinical and Experimental Health Sciences 13/1 (March 2023), 212-217. https://doi.org/10.33808/clinexphealthsci.1099582.
JAMA Muhammad Umar R, Can ZY, Güven E, Karataş Koçberber E, Olmez OF. The Prevalence of Drug-Drug Interactions and Reported Therapy Related Side Effects in Oncology Out-Patients. Clinical and Experimental Health Sciences. 2023;13:212–217.
MLA Muhammad Umar, Rashida et al. “The Prevalence of Drug-Drug Interactions and Reported Therapy Related Side Effects in Oncology Out-Patients”. Clinical and Experimental Health Sciences, vol. 13, no. 1, 2023, pp. 212-7, doi:10.33808/clinexphealthsci.1099582.
Vancouver Muhammad Umar R, Can ZY, Güven E, Karataş Koçberber E, Olmez OF. The Prevalence of Drug-Drug Interactions and Reported Therapy Related Side Effects in Oncology Out-Patients. Clinical and Experimental Health Sciences. 2023;13(1):212-7.

14639   14640